216 related articles for article (PubMed ID: 20868698)
1. Central administration of NPY or an NPY-Y5 selective agonist increase in vivo extracellular monoamine levels in mesocorticolimbic projecting areas.
Quarta D; Leslie CP; Carletti R; Valerio E; Caberlotto L
Neuropharmacology; 2011; 60(2-3):328-35. PubMed ID: 20868698
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
[TBL] [Abstract][Full Text] [Related]
3. Effect of a novel neurotensin analog, NT69L, on nicotine-induced alterations in monoamine levels in rat brain.
Liang Y; Boules M; Shaw AM; Williams K; Fredrickson P; Richelson E
Brain Res; 2008 Sep; 1231():6-15. PubMed ID: 18687313
[TBL] [Abstract][Full Text] [Related]
4. In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist.
Leggio GM; Cathala A; Neny M; Rouge-Pont F; Drago F; Piazza PV; Spampinato U
J Neurochem; 2009 Oct; 111(2):614-23. PubMed ID: 19702657
[TBL] [Abstract][Full Text] [Related]
5. Effect of co-administration of varenicline and antidepressants on extracellular monoamine concentrations in rat prefrontal cortex.
Rollema H; Wilson GG; Lee TC; Folgering JH; Flik G
Neurochem Int; 2011 Jan; 58(1):78-84. PubMed ID: 21056607
[TBL] [Abstract][Full Text] [Related]
6. Effects of neuropeptide Y on food intake and brain biogenic amines in the rainbow trout (Oncorhynchus mykiss).
Aldegunde M; Mancebo M
Peptides; 2006 Apr; 27(4):719-27. PubMed ID: 16253390
[TBL] [Abstract][Full Text] [Related]
7. R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum.
Ichikawa J; Meltzer HY
J Pharmacol Exp Ther; 1999 Dec; 291(3):1227-32. PubMed ID: 10565846
[TBL] [Abstract][Full Text] [Related]
8. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens.
Kuroki T; Meltzer HY; Ichikawa J
J Pharmacol Exp Ther; 1999 Feb; 288(2):774-81. PubMed ID: 9918588
[TBL] [Abstract][Full Text] [Related]
9. In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine.
Jordan S; Kramer GL; Zukas PK; Moeller M; Petty F
Synapse; 1994 Dec; 18(4):294-7. PubMed ID: 7886621
[TBL] [Abstract][Full Text] [Related]
10. Neurochemical interaction between dopaminergic and noradrenergic neurons in the medial prefrontal cortex.
Pan WH; Yang SY; Lin SK
Synapse; 2004 Jul; 53(1):44-52. PubMed ID: 15150740
[TBL] [Abstract][Full Text] [Related]
11. Systemic administration of ghrelin increases extracellular dopamine in the shell but not the core subdivision of the nucleus accumbens.
Quarta D; Di Francesco C; Melotto S; Mangiarini L; Heidbreder C; Hedou G
Neurochem Int; 2009 Feb; 54(2):89-94. PubMed ID: 19118592
[TBL] [Abstract][Full Text] [Related]
12. Neuropeptide Y1 and Y5 receptors mediate the effects of neuropeptide Y on the hypothalamic-pituitary-thyroid axis.
Fekete C; Sarkar S; Rand WM; Harney JW; Emerson CH; Bianco AC; Beck-Sickinger A; Lechan RM
Endocrinology; 2002 Dec; 143(12):4513-9. PubMed ID: 12446577
[TBL] [Abstract][Full Text] [Related]
13. L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist.
Kanatani A; Ishihara A; Iwaasa H; Nakamura K; Okamoto O; Hidaka M; Ito J; Fukuroda T; MacNeil DJ; Van der Ploeg LH; Ishii Y; Okabe T; Fukami T; Ihara M
Biochem Biophys Res Commun; 2000 May; 272(1):169-73. PubMed ID: 10872822
[TBL] [Abstract][Full Text] [Related]
14. Neuropeptide Y suppresses absence seizures in a genetic rat model primarily through effects on Y receptors.
Morris MJ; Gannan E; Stroud LM; Beck-Sickinger AG; O'Brien TJ
Eur J Neurosci; 2007 Feb; 25(4):1136-43. PubMed ID: 17331209
[TBL] [Abstract][Full Text] [Related]
15. The selective neuropeptide Y Y5 agonist [cPP(1-7),NPY(19-23),Ala31,Aib32,Gln34]hPP differently modulates emotional processes and body weight in the rat.
Morales-Medina JC; Dominguez-Lopez S; Gobbi G; Beck-Sickinger AG; Quirion R
Behav Brain Res; 2012 Aug; 233(2):298-304. PubMed ID: 22613731
[TBL] [Abstract][Full Text] [Related]
16. Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor.
Criscione L; Rigollier P; Batzl-Hartmann C; Rüeger H; Stricker-Krongrad A; Wyss P; Brunner L; Whitebread S; Yamaguchi Y; Gerald C; Heurich RO; Walker MW; Chiesi M; Schilling W; Hofbauer KG; Levens N
J Clin Invest; 1998 Dec; 102(12):2136-45. PubMed ID: 9854049
[TBL] [Abstract][Full Text] [Related]
17. Effects of neuropeptide Y (NPY) and [D-Trp32]NPY on monoamine and metabolite levels in dialysates from rat hypothalamus during feeding behavior.
Matos FF; Guss V; Korpinen C
Neuropeptides; 1996 Aug; 30(4):391-8. PubMed ID: 8914867
[TBL] [Abstract][Full Text] [Related]
18. Nicotine-induced monoamine neurotransmitter changes in the brain of young rats.
Shearman E; Fallon S; Sershen H; Lajtha A
Brain Res Bull; 2008 Aug; 76(6):626-39. PubMed ID: 18598854
[TBL] [Abstract][Full Text] [Related]
19. Selective activation of central NPY Y1 vs. Y5 receptor elicits hyperinsulinemia via distinct mechanisms.
Gao J; Ghibaudi L; Hwa JJ
Am J Physiol Endocrinol Metab; 2004 Oct; 287(4):E706-11. PubMed ID: 15187000
[TBL] [Abstract][Full Text] [Related]
20. The effects of acetaldehyde on nicotine-induced transmitter levels in young and adult brain areas.
Sershen H; Shearman E; Fallon S; Chakraborty G; Smiley J; Lajtha A
Brain Res Bull; 2009 Aug; 79(6):458-62. PubMed ID: 19389462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
